All In Biotech

Drug Trial Radar · NCT06246149

Adjuvant Tebentafusp in High Risk Ocular Melanoma

Adjuvant Tebentafusp (IMCgp100) Versus Observation in HLA-A*02:01 Positive Patients Following Definitive Treatment of High-risk Uveal Melanoma: an EORTC Randomized Phase III Study (ATOM Trial)

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 290 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

290

Planned (sponsor's estimate)

Start

Nov 11, 2024

Primary completion

Nov 2032

Study completion Nov 2032

Sponsor

Sponsor type
Research network
Collaborators
Northwell Health; Immunocore Ltd
First posted
Feb 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in patients with metastatic uveal melanoma in a randomized trial. Based on the results in the advanced setting, it is hypothesized that treatment with tebentafusp may reduce the risk of development of disease recurrence.

Conditions

  • Uveal Melanoma

Interventions

  • TebentafuspDrug

    Tebentafusp will be administered weekly i.v.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence-Free survival (RFS)Time frame: 8.1 years from first patient in

Locations

15 sites in 9 countries. Site status is shown where the registry gives one.

  • Northwell Health -Center for Advanced Medicine

    Lake Success, New York · Recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Recruiting

  • Centre Antoine Lacassagne

    Nice, France · Recruiting

  • Institut Curie - Hôpital de Paris

    Paris, France · Recruiting

  • Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin

    Berlin, Germany · Recruiting

  • Universitaets Krankenhaus Eppendorf - Universitaetsklinikum Hamburg-Eppendorf KE - University Cancer Center

    Hamburg, Germany · Recruiting

  • Universitaetsklinikum Heidelberg - Frauenklinik / Hautklinik

    Heidelberg, Germany · Recruiting

  • Leiden University Medical Centre

    Leiden, Netherlands · Recruiting

  • Erasmus MC

    Rotterdam, Netherlands · Recruiting

  • Maria Sklodowska-Curie Memorial Cancer Centre - Maria Sklodowska-Curie National Research Institute of Oncology

    Warsaw, Poland · Recruiting

  • Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia)

    L'Hospitalet de Llobregat, Spain · Recruiting

  • Hospital Clinico Universitario De Valladolid

    Valladolid, Spain · Recruiting

  • Sahlgrenska Universitetssjukhuset

    Gothenburg, Sweden · Recruiting

  • The Clatterbridge cancer Center NHS foundation Trust - Clatterbridge Cancer Center - Liverpool

    Liverpool, United Kingdom · Recruiting

  • East and North Hertfordshire NHS Trust - Mount Vernon Hospital

    Northwood, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.